Hong Kong Medical Equipment Stock News

Why this new collaboration matters for CARsgen Therapeutics Holdings (SEHK:2171) CARsgen Therapeutics Holdings (SEHK:2171) just announced a clinical collaboration with Dispatch Bio to run a Phase 1 trial in China, testing a combined approach for treating solid tumors using both companies' immunotherapies. The study, planned to begin in 2026, will evaluate DISP-11, which uses Dispatch's Flare platform and DV-10 tumor specific virus together with CARsgen's zevorcabtagene autoleucel, or zevor...

Despite an already strong run, Weichai Power Co., Ltd. ( HKG:2338 ) shares have been powering on, with a gain of 26% in...

Key Insights Insiders appear to have a vested interest in Tesson Holdings' growth, as seen by their sizeable ownership...

The Winshine Science Company Limited ( HKG:209 ) share price has done very well over the last month, posting an...

For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...

The Chengdu SIWI Science and Technology Company Limited ( HKG:1202 ) share price has done very well over the last...

As Asia's markets navigate a complex landscape of regulatory changes and economic shifts, investors are increasingly focused on opportunities that provide stable returns amidst volatility. In this environment, dividend stocks stand out for their potential to deliver consistent income, making them an attractive option for those looking to balance growth prospects with reliable payouts.

With a price-to-sales (or "P/S") ratio of 0.3x Lerado Financial Group Company Limited ( HKG:1225 ) may be sending very...

Unfortunately for some shareholders, the EverChina Int'l Holdings Company Limited ( HKG:202 ) share price has dived 26...

China Resources Beer (Holdings) (HKG:291) has had a rough month with its share price down 4.8%. However, a closer look...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Public...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...

As Asian markets navigate a complex landscape of regulatory changes and economic shifts, investors are increasingly focused on identifying stocks that may be priced below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and resilience to market fluctuations, making it an attractive option for those seeking potential opportunities in undervalued equities.

Alco Holdings Limited ( HKG:328 ) shares have had a really impressive month, gaining 49% after a shaky period...

With a price-to-earnings (or "P/E") ratio of 9.8x Yankuang Energy Group Company Limited ( HKG:1171 ) may be sending...

Grand Pharmaceutical Group recently reported that China’s NMPA accepted its New Drug Application for TLX591-CDx (Illuccix®, gallium Ga 68 PSMA-11) for prostate cancer diagnosis, following positive Phase III data showing a 94.8% positive predictive value in Chinese patients with biochemically recurrent disease. Alongside this, the company outlined a broad push in nuclear medicine, with multiple Y-90 liver cancer indications cleared in the US and Europe and several radiopharmaceuticals...

Huaneng Power International, Inc. recently reported preliminary consolidated electricity sales for the fourth quarter and full year 2025, with power plants in the PRC selling 106.112 billion kWh in the quarter and 437.563 billion kWh for the year, both showing year-on-year declines. The annual sales decrease of 3.39% highlights a meaningful pullback in electricity demand or utilization across the company’s Chinese fleet, raising questions about underlying operating conditions. We will now...

Mongolian Mining Corporation released unaudited operational results for the quarter ended 31 December 2025, reporting higher run-of-mine coal output and increased washed coking coal production versus a year earlier. The company also reported full-year growth in washed coking coal sales volumes and continued to advance its copper-silver-gold project pipeline in Mongolia, underscoring a broader resource portfolio. We will now examine how higher washed coking coal sales and progress in...

This article examines whether CK Hutchison Holdings is attractively priced at its current level, or if the recent strength has already reflected much of its value, by breaking down what the numbers may indicate about the stock. With the share price at HK$61.35 and returns of 3.5% over 7 days, 12.6% over 30 days, 13.6% year to date, 60.9% over 1 year, 46.0% over 3 years, and 41.8% over 5 years, many investors are considering whether the current price is consistent with its...

WuXi Biologics (Cayman) (SEHK:2269) recently reported two compliance and technology milestones: fresh UK MHRA GMP certifications for key Wuxi plants and the launch of its PatroLabTM digital twin bioprocess platform. See our latest analysis for WuXi Biologics (Cayman). The latest compliance wins and PatroLabTM launch come as the share price sits at HK$38.4, with a 30-day share price return of 15.87% and a 1-year total shareholder return of 117.69%, while longer term three and five year total...

In January 2026, Blue Moon Group Holdings Limited announced earnings guidance indicating it expects at least a 50% reduction in its loss attributable to equity holders for 2025 compared with the approximately HK$749.30 million loss recorded for 2024. The company attributes this anticipated improvement to tighter cost optimisation, streamlined operations and continued investment in new product promotion and channel expansion, particularly for concentrated liquid laundry detergents. Next, we...

Lonking Holdings Limited recently issued earnings guidance for the year ended December 31, 2025, expecting net profit of about RMB 1,250 million to RMB 1,330 million, implying a significant increase of 23% to 31% versus the prior year. The company attributes this stronger profitability to growth in domestic and export sales, a larger contribution from high-value-added new products, and successful efforts to improve quality, control costs, and lift overall gross profit margins. Next, we will...

Earlier in January 2026, Citi and JPMorgan published upbeat research on China’s life insurance industry, highlighting wealth reallocation, stable margins and stronger fundamentals across Asian insurers. Both banks singled out China Life Insurance as a preferred industry leader, suggesting it could be a key beneficiary of any sector-wide re-rating and regulatory-driven divergence. Next, we’ll examine how this supportive analyst sentiment, particularly around wealth reallocation into insurance...

In January 2026, China Shenhua Energy reported its December and full-year 2025 operating figures, showing higher monthly coal, polyethylene and polypropylene sales but lower annual coal sales, commercial coal production and gross power generation compared with the previous year. This contrast between stronger end-of-year monthly performance and softer full-year volumes gives investors fresh data points on the resilience and volatility of its core coal and power operations. We will now...